OLIPLAT FOR INJECTION 100 mg

国家: 马来西亚

语言: 英文

来源: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

现在购买

资料单张 资料单张 (PIL)
21-11-2019
产品特点 产品特点 (SPC)
22-06-2022

有效成分:

OXALIPLATIN

可用日期:

MYLAN HEALTHCARE SDN. BHD.

INN(国际名称):

OXALIPLATIN

每包单位数:

1vial Vials

厂商:

Onco Therapies Limited

资料单张

                                Not Applicable
                                
                                阅读完整的文件
                                
                            

产品特点

                                FRONT SIDE
PRODUCT DESCRIPTION
Oliplat for Injection 50 mg is a white lyophilized powder or plug.
After
reconstitution with 5% w/v Dextrose injection, the reconstituted
solution is a
clear colorless solution.
Oliplat for Injection 100 mg is a white lyophilized powder or plug.
After
reconstitution with 5% w/v Dextrose injection, the reconstituted
solution is a
clear colorless solution.
COMPOSITION
Each vial of Oliplat for Injection 50 mg contains sterile lyophilized
powder of
Oxaliplatin 50 mg.
Each vial of Oliplat for Injection 100 mg contains sterile lyophilized
powder of
Oxaliplatin 100 mg.
PHARMACOLOGY
Oxaliplatin is an antineoplastic drug belonging to a new class of
platinum-
based compounds, in which the platinum atom is complexed with
1,2-diaminocyclohexane (DACH) and an oxalate group. Oxaliplatin is a
single
enantiomer.
Oxaliplatin exhibits a wide spectrum of both _in vitro_ cytotoxicity
and _in vivo_
antitumor activity in a variety of tumor models. Oxaliplatin also
demonstrates
in _in vitro_ and _in vivo_ activity in various cisplatin resistant
models.
A synergistic cytotoxic action has been observed in combination with
5-fluorouracil both _in vitro_ and _in vivo_.
Studies on the mechanism of action of oxaliplatin, even if this one is
not
completely understood, support the concept that biotransformed,
aquated
products of oxaliplatin interact with DNA to form intra and
interstrand
crosslinks, resulting in disruption of DNA synthesis leading to
cytotoxicity and
antitumor effects.
PHARMACOKINETICS
The pharmacokinetics of platinum in plasma, ultrafiltered plasma and
red
blood cells following a 2-hr oxaliplatin infusion of 130 mg/m
2
every 3 weeks
for 1-5 cycles, are as follows:
C
end
(mcg/
ml)
C
max
(mcg/
ml)
T
max
(hr)
AUC
0-48
(mcg/
ml.hr)
AUC
0-∞
(mcg/
ml.hr)
t
1/2
α
(hr)
t
1/2ß
(hr)
t
1/2
γ
(hr)
V
ss
(L)
Cl
(L/hr)
Ultrafiltrated
Plasma
Mean SD
1.21
0.10
1.21
0.10
2
8.2
2.4
11.9
4.6
0.28
0.06
16.3
2.9
273
19
582
261
10.1
3.07
Mean AUC
0-48
, C
end
and C
max
values were calculated on Cycle 5
Mean AUC
0
                                
                                阅读完整的文件
                                
                            

搜索与此产品相关的警报